GENMAB AS DKK1 (OTCMKTS:GNMSF) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday. The firm presently has a $177.00 price target on the stock. Zacks Investment Research’s target price suggests a potential upside of 11.85% from the company’s previous close.

According to Zacks, “Genmab A/S is a biotechnology company that creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. Genmab has numerous products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions, and intends to continue assembling a broad portfolio of new therapeutic products. In addition, Genmab has developed UniBody, a new proprietary technology that creates a stable, smaller antibody format. Genmab has operations in Europe and the US. “

Separately, JPMorgan Chase & Co. began coverage on shares of GENMAB AS DKK1 in a research report on Tuesday, June 21st. They set a “neutral” rating on the stock.

Shares of GENMAB AS DKK1 (OTCMKTS:GNMSF) remained flat at $158.25 during midday trading on Tuesday. The company has a market cap of $9.47 billion, a PE ratio of 94.14 and a beta of 0.89. The stock’s 50-day moving average price is $172.39 and its 200 day moving average price is $158.34. GENMAB AS DKK1 has a 52 week low of $93.25 and a 52 week high of $183.00.

Receive News & Ratings for GENMAB AS DKK1 Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GENMAB AS DKK1 and related companies with's FREE daily email newsletter.